Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:lup.lub.lu.se:3426efc1-7bee-4d30-9ea9-64fa4efdfdc6" > Low BRAF and NRAS e...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Birkeland, Einar (author)

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma

Article/chapterEnglish2013

Publisher, publication year, extent ...

2013-05-15
Springer Science and Business Media LLC,2013

Numbers

LIBRIS-ID:oai:lup.lub.lu.se:3426efc1-7bee-4d30-9ea9-64fa4efdfdc6
https://lup.lub.lu.se/record/4274284URI
https://doi.org/10.1007/s10585-013-9587-4DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:art swepub-publicationtype
Subject category:ref swepub-contenttype

Notes

Metastatic melanoma is characterized by a poor response to chemotherapy. Furthermore, there is a lack of established predictive and prognostic markers. In this single institution study, we correlated mutation status and expression levels of BRAF and NRAS to dacarbazine (DTIC) treatment response as well as progression-free and overall survival in a cohort of 85 patients diagnosed with advanced melanoma. Neither BRAF nor NRAS mutation status correlated to treatment response. However, patients with tumors harboring NRAS mutations had a shorter overall survival (p < 0.001) compared to patients with tumors wild-type for NRAS. Patients having a clinical benefit (objective response or stable disease at 3 months) on DTIC therapy had lower BRAF and NRAS expression levels compared to patients progressing on therapy (p = 0.037 and 0.003, respectively). For BRAF expression, this association was stronger among patients with tumors wild-type for BRAF (p = 0.005). Further, low BRAF as well as NRAS expression levels were associated with a longer progression-free survival in the total population (p = 0.004 and < 0.001, respectively). Contrasting low NRAS expression levels, which were associated with improved overall survival in the total population (p = 0.01), low BRAF levels were associated with improved overall survival only among patients with tumors wild-type for BRAF (p = 0.013). These findings indicate that BRAF and NRAS expression levels may influence responses to DTIC as well as prognosis in patients with advanced melanoma.

Subject headings and genre

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology hsv//eng
Melanoma
BRAF
NRAS
Chemoresistance
Dacarbazine

Added entries (persons, corporate bodies, meetings, titles ...)

Busch, Christian (author)
Berge, Elisabet Ognedal (author)
Geisler, Jurgen (author)
Jönsson, Göran BLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)onk-gjo (author)
Lillehaug, Johan Richard (author)
Knappskog, Stian (author)
Lonning, Per Eystein (author)
Bröstcancer-genetikSektion I (creator_code:org_t)

Related titles

In:Clinical and Experimental Metastasis: Springer Science and Business Media LLC30:7, s. 867-8761573-72760262-0898

Internet link

Find in a library

Clinical and Experimental Metastasis (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Birkeland, Einar; Busch, Christian; Berge, Elisabet ...; Geisler, Jurgen; Jönsson, Göran B; Lillehaug, Johan ...; show more...; Knappskog, Stian; Lonning, Per Eys ...; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cancer and Oncol ...

Articles in the publication: Clinical and Exp ...

By the university: Lund University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se